Module

How Well Tolerated Can First-Line Therapy Be?

Source: Redefining the Frontiers of First-Line Antiretroviral Therapy: A Decade of Progress in Effective HAART

How Well Tolerated Can First-Line Therapy Be?

Program Director: Joseph J. Eron, Jr., MD

Faculty:

William G. Powderly, MD

CME CREDIT INFORMATION

Release Date: 09/30/06

Expiration Date: 09/29/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

List risk factors for acute antiretroviral toxicity, including genetic correlates
Describe long-term complications of antiretroviral therapy
Explain treatment strategies for management of antiretroviral toxicity

Topics covered include:

Introduction: The Role of Toxicity in Selection of First-Line HAART
Early, Potentially Life-Threatening Toxicities
Early, Troublesome Adverse Effects
Long-term Complications
Body Composition Changes
Cardiovascular Disease
Potential Relationship of Renal Impairment With Antiretroviral Therapy
Conclusion
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.